The reimbursement environment in the United States continues to push towards the creation and delivery of “high-value healthcare”.  High-value healthcare has varied definitions, but reasonably includes such factors as short and long-term clinical outcomes, patient satisfaction and quality of life, and purchaser return on investment – productivity or quality life years gained at an accessible and affordable cost.  This meeting is the third in a series of yearly sessions designed to convene multidisciplinary stakeholders to build consensus around initiatives to align quality and cost in Hematopoietic Cell Transplant (HCT), also known as Bone Marrow Transplant, with the goal of moving the transplant community toward the delivery of high-value healthcare.  

Many transplant physicians are unaware of the increasing focus on quality and value for all healthcare services, particularly those that are resource-intensive.  HCT is a high-cost procedure for which the field must demonstrate the impact they have on the lives of their patient population in order to retain coverage.  Finally, it will be imperative for the field to find cost-effective ways to deliver care as reimbursement rates decrease and bundled payment mechanisms increase.

The primary goal of this forum is to come to consensus around quality initiatives and create pathways for the health plan representatives, physicians, hospital administrators, healthcare purchasers and quality organization leaders to use within their organizations.  Attendees of this forum will create an initial framework to create pathways for the future of quality and value in HCT.  The meeting proceedings will be submitted for publication.